

Special Issue

Bacterial and Viral Infections: Current Challenges and Vaccine Innovations

Message from the Guest Editor

Dear colleagues, This Special Issue brings together cutting-edge research and perspectives on the development, deployment, and impact of vaccines, with a focus on bacterial infections and their role in addressing antimicrobial resistance, as well as viral infections of global concern. It explores a wide range of topics, including the following:

- Advances in vaccine platforms, including mRNA, viral vectors, and protein-based designs, for bacterial and viral targets.
- The role of vaccines in addressing persistent and emerging infectious diseases, such as tuberculosis, pneumococcal infections, influenza, and COVID-19, with a focus on reducing antibiotic use and mitigating antimicrobial resistance.
- Real-world effectiveness and implementation challenges, such as strategies to improve access, equity, and uptake.

This Special Issue aims to highlight the transformative potential of vaccines while addressing key challenges in their development and deployment. It provides a comprehensive resource for researchers, clinicians, and policymakers working to harness the power of vaccines in the fight against bacterial and viral infections.

Guest Editor

Dr. Dima El Safadi

Liverpool School of Tropical Medicine, Department of Clinical Sciences,
Liverpool L7 8XZ, UK

Deadline for manuscript submissions

30 November 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/231757

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).